Cystic Fibrosis Trials: CDER Officials Disagree Over Value Of FEV1 Endpoint
Executive Summary
There is an apparent split within FDA's Center for Drug Evaluation and Research on the usefulness of measuring the amount of air a patient can blow in one second as a primary outcome measure in trials of aerosolized antimicrobial drugs for cystic fibrosis.